Important step towards improving diagnosis and treatment of brain metastases

Important step towards improving diagnosis and treatment of brain metastases

Brain metastases often occur as a result of advanced cancer and, despite medical innovations, are still associated with a poor prognosis. Now, an international expert committee has taken an important step towards improving diagnostics and therapy monitoring. A special imaging procedure, amino acid PET, can not only improve patient care, but also advance research into the development of new treatment approaches.

RANO criteria for response assessment of brain metastases based on amino acid PET imaging

Novel diagnostic and therapeutic opportunities are needed to improve medical care and outcome of patients with brain metastases, a frequent and severe complication of several cancer types. Currently, magnetic resonance imaging (MRI) is the primary method used for detection, treatment planning and disease monitoring in patients with brain metastases, but this method has limitations. These limitations mean that MRI can inform on lesion size but ca…

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

Brain metastases often occur as a result of advanced cancer, and despite medical innovations, are still associated with a poor prognosis.

Generally, when a new treatment appears, the relevant academic society works with the Ministry of Health, Labor and Welfare to create standards for the operation, and the Ministry of Health, Labor and Welfare issues approval to the manufacturer under the Pharmaceuticals and Medical Devices Act, provided that the standards are followed.

ISMRM: Trimodal PET-MR-FUS may be feasible therapy monitoring option

Researchers at ISMRM 2025 touted the success of a trimodal MR-PET-FUS system that could have applications for therapy monitoring.

When cancer reaches the brain, everything changes for many sufferers. Dr. Matthias Preusser answers in the podcast how new therapy methods can help.